Palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) are three FDA-approved CDK4/6 inhibitors for the treatment of advanced HR+/HER2– breast cancer (George et al., 2021). Here, CDK4 is linked to breast carcinoma.